The Biomedical Translation Fund will be run by OneVentures, Brandon Capital and BioScience Managers.
Tag Archives | Asia-Pacific
German venture capital-backed cancer drug maker Ganymed Pharmaceuticals has been acquired by Japanese pharma company Astellas Pharma for €422 million.
At the China Everbright Investor Conference, FountainVest Partners chief executive Frank Tang highlighted potential deals in healthcare and advanced manufacturing.
The Singaporean fund is increasing its bets in the industry as Asia’s rising middle class spend more on healthcare services.
NSSK, a private equity firm that spun out of TPG Capital’s Japanese division in 2014, invests in businesses that focus on Japan’s ageing population, healthcare, services, and leisure.
Raphael Arndt, the chief investment officer of Australia’s A$122.8 billion Future Fund, said the fund is looking at opportunities in Chinese healthcare.
CVC Capital Partners has paid 2.2 trillion rupiah ($166m) to acquire a 15 percent stake in PT Siloam International Hospitals, Indonesia’s largest private hospital group.
The Australian private equity powerhouse, which owns ICON Cancer Care, raised A$980m for the vehicle in less than two months.
The private equity powerhouse, whose Japan-focused buyout fund has so far targeted mid-caps, could be eyeing a deal for Takeda Pharmaceutical’s laboratory chemical producer Wako.
The transaction marks the first cross-border healthcare deal led by a Chinese strategic into the European market in 2016.